KEYMED BIO-B 02162Hong Kong Stock Exchange

78.3003.57%( +2.700 )
Closed: Oct 9 · Delayed · Hong Kong Stock Exchange
KEYMED BIO-B (02162) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2021-07-08
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG5252B1023
Southbound Connect
Shanghai · Shenzhen

Industry

Innovative Drugs & Biologics 0.02%
124 stocks in this industry
Down 52 Up 57
Industry RankingsValue (HKD)Rank
Revenue (Last FY)840.00M58/112
Net Profit (Last FY)-612.88M110/125
ROE (Last FY)-18.84%77/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
Bo CHEN Executive Director
Changyu WANG Executive Director
Gang XU Executive Director
Qi CHEN Non-Executive Director
Yilun LIU Non-Executive Director
Xiao-Fan WANG Independent Non-Executive Director
Yang KE Independent Non-Executive Director
Cheuk Kin Stephen LAW Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-09-06.

About this page

This page shows KEYMED BIO-B (02162) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.